Leishmaniasis affecting the skin. It is the most common form of leishmaniasis. It presents with erythematous macules and papules, and nodules which may eventually ulcerate. The lesions appear in the b...
Comprehensive, easy-to-understand information about this condition
How we create this content →The documentation surrounding cutaneous leishmaniasis is limited due to its classification as a rare disease, affecting fewer people in certain regions. The lack of systematic clinical studies and the absence of well-defined genetic factors contribute to the challenges in understanding this condition comprehensively. Ongoing research aims to enhance our knowledge and treatment options.
To navigate cutaneous leishmaniasis, consider consulting a dermatologist with experience in tropical diseases or infectious diseases. You can also explore clinical trials that may offer access to new treatments. A valuable resource is ClinicalTrials.gov for finding ongoing studies. While there are currently no specific patient organizations, keeping informed through reliable medical websites can be beneficial.
There are several orphan drugs designated for cutaneous leishmaniasis, including Imiquimod-Ferulic Acid, oleylphosphocholine, and a parasite-selective proteasome inhibitor targeting kinetoplastid parasites, alongside the FDA-approved treatment, miltefosine. Currently, there are 16 active clinical trials investigating various aspects of this condition. For more information on these trials, you can visit ClinicalTrials.gov and search for cutaneous leishmaniasis.
Actionable guidance for navigating care for cutaneous leishmaniasis
To navigate cutaneous leishmaniasis, consider consulting a dermatologist with experience in tropical diseases or infectious diseases. You can also explore clinical trials that may offer access to new treatments. A valuable resource is ClinicalTrials.gov for finding ongoing studies. While there are currently no specific patient organizations, keeping informed through reliable medical websites can be beneficial.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation surrounding cutaneous leishmaniasis is limited due to its classification as a rare disease, affecting fewer people in certain regions. The lack of systematic clinical studies and the absence of well-defined genetic factors contribute to the challenges in understanding this condition comprehensively. Ongoing research aims to enhance our knowledge and treatment options.
To navigate cutaneous leishmaniasis, consider consulting a dermatologist with experience in tropical diseases or infectious diseases. You can also explore clinical trials that may offer access to new treatments. A valuable resource is ClinicalTrials.gov for finding ongoing studies. While there are currently no specific patient organizations, keeping informed through reliable medical websites can be beneficial.
There are several orphan drugs designated for cutaneous leishmaniasis, including Imiquimod-Ferulic Acid, oleylphosphocholine, and a parasite-selective proteasome inhibitor targeting kinetoplastid parasites, alongside the FDA-approved treatment, miltefosine. Currently, there are 16 active clinical trials investigating various aspects of this condition. For more information on these trials, you can visit ClinicalTrials.gov and search for cutaneous leishmaniasis.
Actionable guidance for navigating care for cutaneous leishmaniasis
To navigate cutaneous leishmaniasis, consider consulting a dermatologist with experience in tropical diseases or infectious diseases. You can also explore clinical trials that may offer access to new treatments. A valuable resource is ClinicalTrials.gov for finding ongoing studies. While there are currently no specific patient organizations, keeping informed through reliable medical websites can be beneficial.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation surrounding cutaneous leishmaniasis is limited due to its classification as a rare disease, affecting fewer people in certain regions. The lack of systematic clinical studies and the absence of well-defined genetic factors contribute to the challenges in understanding this condition comprehensively. Ongoing research aims to enhance our knowledge and treatment options.
To navigate cutaneous leishmaniasis, consider consulting a dermatologist with experience in tropical diseases or infectious diseases. You can also explore clinical trials that may offer access to new treatments. A valuable resource is ClinicalTrials.gov for finding ongoing studies. While there are currently no specific patient organizations, keeping informed through reliable medical websites can be beneficial.
There are several orphan drugs designated for cutaneous leishmaniasis, including Imiquimod-Ferulic Acid, oleylphosphocholine, and a parasite-selective proteasome inhibitor targeting kinetoplastid parasites, alongside the FDA-approved treatment, miltefosine. Currently, there are 16 active clinical trials investigating various aspects of this condition. For more information on these trials, you can visit ClinicalTrials.gov and search for cutaneous leishmaniasis.
Actionable guidance for navigating care for cutaneous leishmaniasis
To navigate cutaneous leishmaniasis, consider consulting a dermatologist with experience in tropical diseases or infectious diseases. You can also explore clinical trials that may offer access to new treatments. A valuable resource is ClinicalTrials.gov for finding ongoing studies. While there are currently no specific patient organizations, keeping informed through reliable medical websites can be beneficial.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
Organizations with orphan designations or approved therapies for this disease